William Sharfman

Associate Professor

1990 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Interleukin-1alpha Medicine & Life Sciences
Safety Medicine & Life Sciences
Skin Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2018

Radiosurgery
metastasis
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
lungs

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting

Rowe, S. P., Luber, B., Makell, M., Brothers, P., Santmyer, J. A., Schollenberger, M. D., Quinn, H., Edelstein, D. L., Jones, F. S., Bleich, K. B., Sharfman, W. H. & Lipson, E. J., Jan 1 2018, (Accepted/In press) In : Molecular oncology.

Research output: Contribution to journalArticle

Melanoma
DNA
Neoplasms
Tumor Burden
Nuclear Family

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib

Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., Gonzalez, R., Kefford, R., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W., McWilliams, R., Sznol, M., Redhu, S., Gasal, E., Mookerjee, B., Weber, J. & Flaherty, K. T., Mar 1 2018, In : Journal of Clinical Oncology. 36, 7, p. 667-673 7 p.

Research output: Contribution to journalArticle

Melanoma
Mitogen-Activated Protein Kinase Kinases
Safety
Disease-Free Survival
dabrafenib

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Izar, B., Sharfman, W., Hodi, F. S., Lawrence, D., Flaherty, K. T., Amaravadi, R., Kim, K. B., Puzanov, I., Sosman, J., Dummer, R., Goldinger, S. M., Lam, L., Kakar, S., Tang, Z., Krieter, O., Mcdermott, D. F. & Atkins, M. B., 2017, (Accepted/In press) In : Cancer Medicine.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor-2
Melanoma
Mutation
Angiogenesis Modulating Agents
Maximum Tolerated Dose

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Lipson, E. J., Lilo, M. T., Ogurtsova, A., Esandrio, J., Xu, H., Brothers, P., Schollenberger, M., Sharfman, W. H. & Taube, J. M., Mar 21 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 23

Research output: Contribution to journalArticle

Basal Cell Carcinoma
Ligands
Tumor-Infiltrating Lymphocytes
Neoplasms
Tumor Microenvironment